Portal de Periódicos da CAPES

A Retrospective National Study on Colonization Rate and Antimicrobial Susceptibility of Streptococcus agalactiae in Pregnant Korean Women, 2018–2020

2022; Yonsei University College of Medicine; Volume: 63; Issue: 8 Linguagem: Inglês

10.3349/ymj.2022.63.8.717

1976-2437

Hye Gyung Bae, Jungmi Hong, Young-Jin Kim, Kyoung-Ryul Lee, Kyungwon Lee, Seong Jin Choi, Young Uh,

Sepsis Diagnosis and Treatment

Purpose:The prevalence of Group B Streptococcus (GBS) colonization in pregnant Korean women is increasing; however, nationwide studies are lacking.Therefore, we aimed to analyze regional colonization rates and antimicrobial susceptibility for GBS in pregnant Korean women through a nationwide survey.Materials and Methods: From January 2018 to December 2020, data from the Seoul Clinical Laboratories on vaginal swab cultures were retrospectively analyzed to detect maternal GBS carriers.Each swab specimen was inoculated onto a 5% blood agar plate and incubated at 35°C-37°C in a 5% CO2 incubator for 24 h.GBS isolates were identified using a Microflex MALDI Biotyper.Antimicrobial susceptibility tests were performed using the Vitek 2 automated system.Results: The overall nationwide GBS colonization rate in pregnant Korean women was found to be 10.6% (3578/33721).The maternal GBS colonization rates ranged from 10.5%-10.8%over the 3-year study period.The GBS colonization rates by province, in descending order, were as follows: Jeolla-do, 13.2%; Gangwon-do, 12.0%; Chungcheong-do, 11.8%; Gyeonggi-do, 11.3%; Seoul, 10.2%; and Gyeongsang-do, 9.6%.During the study period, the resistance rates against chloramphenicol, levofloxacin, clindamycin, erythromycin, and tetracycline were 2.6%-2.7%,18.2%-19.6%,33.4%-35.7%,35.6%-36.8%,and 50.5%-53.3%,respectively. Conclusion:In pregnant Korean women, GBS colonization rates were in the range of 9.6%-13.2%,with Gyeongsang-do being the lowest and Jeolla-do the highest.The resistance rate against clindamycin was high (33.4%-35.7%).GBS colonization rates during pregnancy should be studied nationwide according to the Centers for Disease Control and Prevention-recommended guidelines with periodic antimicrobial resistance monitoring.